Venus Remedies get marketing nod for six Chemotherapy Drugs

Venus Remedies, a global oncology drug provider, has received marketing approval for six crucial chemotherapy drugs in the Philippines, marking a significant stride in the ASEAN region. These approvals include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, solidifying Venus Remedies' position in the dynamic $420 billion pharmaceutical market of the Philippines. With this achievement, Venus Remedies now holds 525 marketing approvals for its oncology products across 76 countries.

 

Saransh Chaudhary, CEO of Venus Medicine Research Centre, emphasized the company's goal of becoming the premier oncology medicine supplier from India in Southeast Asia. The Philippines' market for cancer drugs, which is projected to grow at a CAGR of 8.7% by 2025, provides immense opportunities for Venus Remedies to expand its operations in the Asia-Pacific region.

 

Additionally, Venus Remedies' oncology wing has received marketing authorization for the chemotherapy drug oxaliplatin in Myanmar, furthering the company's footprint in the ASEAN region. These achievements underscore Venus Remedies' commitment to delivering advanced cancer therapies globally.

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions